You mean THIS kind of "smarter" AI?
Overview
UCLA's ATL-DC (Autologous Tumor Lysate-pulsed Dendritic Cell) and Northwest Biotherapeutics' (NWBO) DCVax are both personalized dendritic cell (DC) vaccines designed to treat glioblastoma (GBM) and other high-grade gliomas by harnessing the patient's immune system. They share a core mechanism: DCs are harvested from the patient's blood, pulsed with tumor antigens from the patient's own resected tumor tissue (via tumor lysate), matured in the lab, and injected back into the patient to stimulate a T-cell response against the tumor. Both have shown promise in extending survival in clinical trials, with mild side effects.
However, they are not identical. ATL-DC refers to UCLA's specific implementation of this DC vaccine technology, developed and tested primarily in academic trials at UCLA's Jonsson Comprehensive Cancer Center. DCVax (specifically DCVax-L for lysate-pulsed) is NWBO's proprietary platform, refined for commercial-scale manufacturing and broader regulatory approval. While some early UCLA trials may have leveraged NWBO's technology or collaborators, current UCLA studies appear to use their in-house ATL-DC formulation.
Market Data 
Markets 
AI
